These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34120295)

  • 1. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia].
    Li JH; Pang NN; Zhang ZH; Zhang R; Chen G; Qu JH
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):198-203. PubMed ID: 28395442
    [No Abstract]   [Full Text] [Related]  

  • 3. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
    Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
    PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
    Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
    Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
    Abo Elwafa R; Abd Elrahman A; Ghallab O
    Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.
    Grywalska E; Smarz-Widelska I; Korona-Głowniak I; Mertowski S; Gosik K; Hymos A; Ludian J; Niedźwiedzka-Rystwej P; Roliński J; Załuska W
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
    Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
    Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.
    Zhou Y; Shi D; Miao J; Wu H; Chen J; Zhou X; Hu D; Zhao C; Deng W; Xie C
    Sci Rep; 2017 Mar; 7():43627. PubMed ID: 28256540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.
    Visco C; Falisi E; Young KH; Pascarella M; Perbellini O; Carli G; Novella E; Rossi D; Giaretta I; Cavallini C; Scupoli MT; De Rossi A; D'Amore ES; Rassu M; Gaidano G; Pizzolo G; Ambrosetti A; Rodeghiero F
    Oncotarget; 2015 Jul; 6(21):18653-63. PubMed ID: 26087198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
    Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
    Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis.
    Grywalska E; Roliński J; Pasiarski M; Korona-Glowniak I; Maj M; Surdacka A; Grafka A; Stelmach-Gołdyś A; Zgurski M; Góźdź S; Malm A; Grabarczyk P; Starosławska E
    PLoS One; 2015; 10(10):e0140178. PubMed ID: 26460692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
    Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
    Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.
    Zhang WT; Zhu GL; Xu WQ; Zhang W; Wang HZ; Wang YB; Li YX
    Diagn Pathol; 2022 Jul; 17(1):61. PubMed ID: 35842661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.